On January 3, 2024, San Diego-based Radionetics Oncology, a clinical stage radiopharmaceutical company, announced that it has raised $52.5 million in Series A fundraising led by Frazier Life Sciences, 5AM Ventures, and new investor, DCVC Bio, with participation from Crinetics Pharmaceuticals, and GordonMD Global Investments. Wilson Sonsini Goodrich & Rosati advised Radionetics Oncology on IP matters related to the transaction.

Proceeds of the financing will be used to advance Radionetics Oncology's pipeline of potent, small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) for the treatment of a broad range of cancers.

The Wilson Sonsini patents and innovations team that advised Radionetics Oncology on the transaction included Val Zunic, Kaia Parenti, and Mike Hostetler.

For more information, please see Radionetics Oncology's news release.